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Abstract 
Influenza virus infection is a major cause of morbidity and mortality in at risk populations. Children, 
especially under the age of two, are at an increased risk of complications associated with influenza virus 
infection. Evidence suggests that a single dose of influenza vaccine does not adequately protect children 
against circulating influenza virus. The Centers for Disease Control and Prevention’s (CDC) Advisory 
Committee on Immunizations Practices (ACIP) recommends two doses of influenza vaccine, spaced at 
least four weeks apart, before the beginning of the influenza season for children between the ages of 6 
months through 8 years receiving influenza vaccine for the first time. The initial dose is thought to prime 
the immune system, and the second dose is thought to mount a protective antibody response.  We 
conducted a systematic literature review to summarize current evidence from randomized controlled trials 
(RCTs) and observational studies that compared immunogenicity and vaccine effectiveness (VE) after 
one or two doses of influenza vaccine in children to evaluate the evidence basis for the CDC 
recommendations. The search identified 727 unique articles and 82 were screened in full text for 
eligibility. A total of 26 studies met inclusion criteria, 16 immunogenicity and 10 VE studies. Overall, the 
evidence demonstrates increased immunogenicity and VE after two doses of influenza vaccine compared 
to one dose in children 6 months through 8 years.  
 
Keywords: influenza vaccine, children, vaccine effectiveness, immunogenicity, fully vaccinated, partially 
vaccinated 
  
Introduction 
 Influenza results in annual epidemics of respiratory illness with associated hospitalizations and 
deaths.  In the United States, there were an estimated 9.2 million to 35.6 million influenza-related 
illnesses, 140,000 to 710,000 influenza-related hospitalizations, and 4,000-20,000 influenza-related 
excess deaths per influenza season during the 2010-11 through 2015-16 seasons.1 Young children aged <5 
years are considered at increased risk for influenza-related complications with an estimated 89 to 620 
emergency department visits and 2 to 16 hospitalizations per 10,000 children.2   School-aged children 
have the highest rates of influenza virus infection and are thought to play a critical role in driving 
community epidemics of influenza.3,4   
 Influenza vaccination is considered the most effective method of influenza prevention.  Because 
influenza viruses continually undergo a process of antigenic drift in which viruses acquire point mutations 
in the genes that encode the two surface proteins responsible for virus binding to the host cell and release 
from infected cells (hemagglutinin (HA) and neuraminidase, respectively), seasonal influenza vaccines 
are updated annually.  Seasonal influenza vaccines include three or four vaccine strains, including two 
strains of influenza A (H1N1 and H3N2), and one or two strains of influenza B (B/Yamagata or 
B/Victoria). Vaccine strains are selected based on the strains predicted to circulate during the upcoming 
influenza season.  Currently licensed influenza vaccines are primarily designed to induce antibodies to the 
HA protein and must be given annually because of antibody waning and annual updates to the vaccine 
strain composition.  Studies evaluating the performance of influenza vaccines either evaluate efficacy or 
effectiveness based on clinical outcomes with laboratory-confirmed influenza considered the gold-
standard, or evaluate immunogenicity based primarily on antibody titers measured using the 
hemagglutination inhibition (HAI) assay. 
The United States Advisory Committee on Immunization Practices (ACIP) currently recommends 
that all persons six months of age and older receive an annual influenza vaccine.5  While the ACIP 
recommends a single annual dose of influenza vaccine for most persons, children aged 6 months through 
8 years of age may require two doses of vaccine depending upon their prior vaccination history.  Since 
2006, the ACIP has recommended that children in this age group receive two doses in the current season 
if they have not previously received influenza vaccine.6  However, recommendations for one versus two 
doses of influenza vaccine have varied since 2006 for children in this age group who either received only 
one prior dose of influenza vaccine or two doses of influenza vaccine given during different influenza 
seasons based in part on whether there were major antigenic differences between the strains in the prior 
and current season’s vaccines and on logistical considerations.  Young children are thought to need two 
doses of influenza vaccine to induce a protective immune response during their first season of vaccination 
because they are more likely to be relatively immunologically naïve to influenza since they may not have 
had prior influenza virus infection and have not previously received vaccine.  However, administering 
two doses of influenza vaccine during the same season is often logistically challenging as it may require 
extra clinic visits outside of routine well child exams and ideally should be done prior to influenza virus 
circulation to provide optimal protection during the current season.  Multiple studies have evaluated the 
efficacy, effectiveness or immunogenicity of one versus two doses of influenza vaccine among young 
children, including a number of studies published since the original 2006 ACIP recommendations for two 
doses of vaccine for children aged 6 months through 8 years in their first season of vaccination.  These 
studies have included children of varying ages and with varying baseline pre-vaccination antibody titers 
to influenza and have used different two-dose vaccination schedules (e.g. giving both doses in the same 
season versus two doses in consecutive influenza seasons) that may include differences in the strain 
composition of doses.  We conducted a systematic review to summarize the current evidence on the 
immunogenicity or effectiveness of two versus one dose of inactivated influenza vaccines (IIV) among 
previously vaccine naïve children aged 6 months through 8 years during their first season of vaccination.  
We also sought to evaluate whether the immunogenicity or effectiveness of two versus one dose varied by 
age, timing of doses (same versus different seasons), antigenic differences in the strain composition of 
doses, and baseline pre-vaccination antibody titers against influenza. 
Methods 
Search Strategy and Selection Criteria 
We systematically searched Medline, Embase, and Cochrane Library databases to include 
literature published up to April 2nd, 2019. No limits were imposed on the year or language of publication. 
The search used combinations of key terms including “influenza vaccine(s)”, and “infant” or “child” or 
“pediatrics”, and “dose” or “two-doses”. The search was limited to manuscripts with available abstracts 
and excluded animal studies, commentaries, editorials, letters, and conference abstracts or papers. A more 
detailed description of the search strategy is provided in Appendix A. In addition, we searched references 
from relevant articles to identify studies not captured in our database search.  
The intervention(s) or exposure(s) of interest were trivalent or quadrivalent inactivated influenza 
vaccines. Eligible studies included randomized controlled trials (RCT) and observational studies (case-
control and cohort studies) that compared the efficacy, effectiveness or immunogenicity of two versus one 
dose of influenza vaccine among healthy children aged 6 months through 8 years. Studies evaluating 
immunogenicity were restricted to those that measured HAI antibody response after each vaccine dose in 
the same group of children. Studies with multiple age groups were included only if results separately 
considered pediatric populations between 6 months through 8 years. Studies were ineligible and were 
excluded if there was no available English text, focused exclusively on  participants ≥9 years, were 
restricted to special populations (e.g., immunosuppressed or asthma), were ongoing, focused on pandemic 
H1N1 monovalent vaccines, or had fewer than thirty participants. Studies were also excluded if they 
focused exclusively on vaccines that were not licensed for clinical use in all children aged 6 months 
through 8 years, including live-attenuated influenza vaccines, which are not currently licensed for 
children aged <2 year in the United States, and adjuvanted vaccines, which are not currently licensed for 
children in the United States.  
Vaccine Effectiveness and Vaccination Status 
 
We included all observational studies fulfilling search criteria that estimated vaccine 
effectiveness (VE) among fully vaccinated (FV) and partially vaccinated (PV) compared to unvaccinated 
(UV) children. VE was assessed against either laboratory-confirmed influenza virus infection or 
medically-attended influenza-like illness (ILI) or acute respiratory infection (ARI) that did not require 
laboratory confirmation.  Laboratory-confirmed cases were determined by either culture or real-time, 
reverse transcription polymerase chain reaction (rRT-PCR). Studies used either cohort or test-negative 
case-control designs to assess VE.  In the test-negative design, the exposure of interest is influenza 
vaccination, and cases and controls are defined as persons with respiratory illness with and without 
laboratory-confirmed influenza, respectively.7  This design is typically used to assess VE against 
medically-attended illness and is thought to be less susceptible to confounding from healthcare seeking 
behaviors.7   
Vaccination status was typically defined by ACIP criteria for each season.  FV was defined as 
two doses received at least four weeks apart in the season under study; depending on the year under 
investigation an alternative definition for FV was at least one dose in a prior season and one dose at least 
14 days before the outcome. PV was defined as children who were not vaccinated in any previous season 
and received one dose in the season under study at least 14 days before the outcome, or two doses in the 
season under study but with the second dose administered less than 14 days before the outcome.  Children 
were considered UV if they received no influenza doses in the season under investigation 
Immunogenicity of One vs Two Doses  
To evaluate the immunogenicity of two versus one dose of IIV, we examined serum  HAI 
antibody titers against influenza A/H1N1, influenza A/H3N2, and influenza B vaccine antigens using 
geometric mean titers (GMTs) after one and two doses of IIV in the same group of children. All studies 
administered the second dose of IIV approximately 4 weeks after the first and serum was collected three 
to four weeks after each dose. For studies that did not publish GMTs as part of their HAI outcome 
measures, we attempted to contact authors to obtain these data for analysis. When contact was not 
successful, we used GetData Graph Digitizer 2.26 software to estimate original (x,y) data from figures 
and graphs.   To compare antibody titers after one and two doses we calculated the Geometric Mean Titer 
Ratio (GMR). GMR was estimated as the log2 of the post-vaccination GMT after two doses divided by 
the log2 of the post-vaccination GMT after one dose. A GMR > 1.0 indicates a higher GMT after the 
second dose. We also calculated the mean fold rise (MFR) from baseline titers to post-vaccination titers 
after the first dose and from baseline titers to post-vaccination titers after the second dose when baseline 
antibody levels were available. MFR was estimated as the log2 of the post-vaccination GMT after one or 
two doses divided by the log2 of the pre-vaccination baseline GMT.  Seroconversion Rates (SCR) were 
identified after one and two doses which was defined by either a pre-vaccination HAI titer < 1:10 and a 
post-vaccination HAI titer ≥ 1:40 or a minimum four-fold rise in post-vaccination HAI titer. We also 
looked at differences in antibody response based on age and baseline antibody titers. Undetectable 
baseline antibody titers was defined as either a titer <1:10,8,9 or <1:8.10 
Results 
Study Selection 
We identified 724 articles from the database searches and 10 more after searching relevant 
bibliographies (Fig. 1).  After duplicate articles were excluded (n= 7), 727 were screened.  After 
screening titles and abstracts, 82 were chosen for full-text review.  Reasons for exclusion included failure 
to meet the inclusion criteria (n= 41), a sample size less than 30 (n= 7), lack of age group specification 
(n= 4), no available English text (n= 3), and vaccine not approved for clinical use (n= 1). In total, 26 
studies met inclusion criteria. Of these 10 were VE studies,11-20  and 16 were immunogenicity trials.8-10,21-
33  We included one study that measured HAI antibody titers after one and two doses in children ages 6 
through 9 years.29  Table 1 summarizes the studies included in this review. 
Vaccine Effectiveness and Vaccination Status 
VE results for each study are summarized in Table 2. Eight  out of 10 VE studies used a test-
negative design to estimate VE against medically-attended, laboratory-confirmed influenza virus 
infection.12-15,17-20  These studies measured VE against influenza-associated outpatient medical visits,18,20 
both outpatient and inpatient medically-attended encounters,12,14,15,19 and influenza-associated 
hospitalizations,13,17  The two remaining studies estimated VE for preventing medically attended ILI and 
pneumonia/influenza medical visits using ICD-9-CM codes without laboratory confirmation of 
influenza.11,16 Vaccine status definition were consistent across the majority of trials with the exception of  
one study which considered spacing of two doses of influenza vaccine ≥14 days,17 instead of four weeks.  
 
Overall, VE against all influenza A and B was higher among FV children compared to UV 
children, than among PV children compared to UV children.  Wide Confidence Intervals (CI)were seen 
across studies, likely due to the relatively small number of cases compared to controls. Most of the studies 
that found significant VE in PV children also found higher VE in FV children,13,15,16 with the exception of 
Thompson et al., which detected higher VE for PV than FV children in the 2012-2013 influenza season 
although confidence intervals for VE estimates among FV and PV children overlapped substantially.20   
One study did not find significant VE estimates for either PV or FV children across the two studied 
influenza seasons when there were suboptimal matches between vaccine strains and circulating influenza 
viruses.12   VE stratified by influenza subtype (i.e. A/H1N1, A/H3N2 and B viruses) was also typically 
higher for FV children compared to PV children (Supplemental Table 1).13,17,20 However, Thompson et al. 
observed a higher VE against A/H3N2 viruses among PV children (VE= 83, 95% CI: 60-93) than among 
FV children (VE= 36, 95% CI: 6-56) (P=0.021) with a 2.7-fold (95% CI: 1.2-6.3) increased odds of being 
influenza A/H3N2 positive if FV compared to PV.20  Interestingly, Buchan et al. also found higher VE 
against A/H3N2 for PV children (VE= 70, 95% CI: 25-88) compared to FV children (VE= 53.3, 95% CI: 
4-77), however all other sub-analyses demonstrated higher VE in FV children.13 In this study, the effect of 
FV status on influenza subtype appeared to be strongest against influenza B (p= 0.03), with higher VE in 
FV children (VE=58%; 95% CI: 28-75) compared to PV children (VE=12%; 95% CI: -45 to 46).13 
 
VE differences by age 
 In the youngest age group, 6-23 months, VE estimates were consistently higher for FV children 
compared to PV children (Table 2). None of the seven studies that estimated VE in children aged 6-23 
months demonstrated significant VE for PV children in this age group.11-14,16,18,19 There was variability 
when comparing VE in children aged 6-23 months to older children. Buchan et al. identified higher VE 
for children 24-59 months compared to children 6-23 months (p= 0.012).13 Shuler et al. found VE 
estimates for children 6-23 months were higher for FV children (VE=52%; 95% CI: 20-70), however in 
children 24-59 months VE was demonstrated in both PV (VE=65%; 95% CI: 30-80) and FV (VE= 45%; 
95% CI 10-70) groups.18. Similarly, Ritzwoller et al. found that infants 6-11 months were 4 to 5 times 
more likely to present with ILI compared to older children aged 7-8 years.16 In contrast, other studies 
found no VE differences across age groups in children under 8 years.14,17 
VE by vaccination schedule or priming  
 Two studies considered the impact of prior influenza vaccination on current season VE.13,20 
Buchan et al. found similar VE estimates overall based on vaccination in current season only compared to 
two sequential seasons (66% versus 62%).13 However, there was variation across seasons. For example, in 
the 2010-2011 season VE was higher when vaccinated in current season only compared to children 
vaccinated in current and prior season (83% vs 72%), however in the 2012-2013 season VE was 67% for 
children vaccinated in current and prior season and only 27% for children vaccinated in the current 
season.13 Thompson et al. measured VE against influenza infection based on priming or doses received in 
previous seasons.20 The study considered four potential definitions for priming (one or more doses 
received in prior season only, one or more doses received in any prior season, two doses across prior 
seasons, and two doses of influenza vaccine received in the same prior season) and then estimated VE for 
each combination of current season and priming definition  (UV and no prime, UV and prime, current 
season only and no prime, and current season with prime).20 A significant effect modification on current 
season VE was seen only when priming was defined as one or more doses received in prior season only 
(P values < 0.1) and two doses of influenza vaccine received in the same prior season (P values <0.5) with 
more significant effect modification for the latter definition.20 Furthermore VE point estimates were 
consistently higher for children who received two doses in a prior season (VE= 58%-80%) compared to 
children who did not (VE=33%-42%).20 Similarly, the odds of being A/H3N2 positive were 2.4 times 
(95% CI: 1.4-4.3) higher among children who received the current season vaccination but were unprimed 
compared to children who received the current season vaccination but were primed with two doses in a 
previous season.20 These findings suggest priming with two doses of influenza vaccination may be more 
effective than one dose.  
Immunogenicity of One vs Two Doses 
Immunogenicity results separated by vaccine strain are summarized in Table 3. There were five 
RCTs that compared antibody responses between inactivated and adjuvanted influenza vaccines;22,28,31,33,34 
data are only included from the groups that received two doses of  IIV. The majority of the 
immunogenicity trials administered a 0.25 ml dose for children < 3 years, and 0.5 ml dose for children ≥3 
years.  However, one study administered a 0.5 ml dose regardless of age,22 and another study 
administered a 0.1 ml dose for children < 1 year and 0.2 ml dose for children ≥ 1 years.27 Two studies 
stratified data by age groups,22,33 and three stratified results by baseline antibody titers.8-10 Of note two of 
the studies that stratified by baseline antibody titers had small numbers in some strata.9,10 
Overall, two doses of IIV were more immunogenic compared to one dose for A/H1N1, A/H3N2, 
and B vaccine antigens (Table 3). GMRs ranged from 0.9 (95% CI:CI: 0.8-1.1) to 8.7 (95% CI: 7.8-9.7) 
against A/H1N1 vaccine antigens, 0.7 (95% CI not reported) to 5.3 (95% CI: 4.7-6.0) against  A/H3N2 
vaccine antigens, and 0.8 (95% CI: 0.5-1.5) to 6.8 (95% CI: 6.0-7.8) against  B vaccine antigens.8-10,21-33  
MFR or value increase of GMTs from baseline were typically higher post dose two compared to post dose 
one. The only exceptions were two studies that stratified GMTs by baseline antibody titers.8,9 MFR 
calculations in these studies increased after each dose in the strata with undetectable baseline antibody 
titers. In contrast, there was almost no change in MFR after dose one and two in the strata with higher 
baseline antibodies. For example, MFR of HAI GMTs against B antigens increased from 3.6 (95% CI: 
3.3-4.0) to 24.6 (95% CI: 22.7-26.7) after one and two doses for children with baseline antibody titers 
<1:10, but remained relatively unchanged for both children with baseline titers ≥1:10 to < 1:40 from 19.2 
(95% CI: 12.1-30.3) after dose one to 16.1 (95% CI: 10.9-23.8) after dose two, and for children with 
baseline titers ≥1:40 from 8.6 (95% CI: 6.3-11.7) to 8.2 (95% CI: 6.3-10.8) with a similar picture for both 
A/H1N1 and A/H3N2 vaccine antigens.9 While this study had small numbers for the two strata with 
detectable baseline titers, a similar relationship is also seen for MFR calculations using Neuzil et al.’s data 
(Table 3).  
In general, higher GMRs were seen in younger children and groups with low pre-vaccination 
baseline titers, and lower GMRs were observed among older children and groups with higher baseline 
antibody titers.  For example, GMR calculations for one study which calculated GMTs stratified by age 
group demonstrated a GMR of 6.1 (95% CI: 4.4-8.4) for infants 6 to 11 months,  6.0 (95% CI: 3.9-9.3) for 
children 12 to 35 months, and 1.7  (95% CI: 1.0-2.9) for children 36-71 months for HAI titers against the 
A/H1N1 vaccine antigen , with a similar pattern for A/H3N2 and B vaccine antigens.22   In addition, all 
three studies that stratified results by baseline antibody titers demonstrated an inverse relationship 
between GMR and baseline antibody titers. For example, GMR calculations for a study that stratified 
results by pre-vaccination baseline HAI titers were 4.1 (95% CI: 3.2 -5.4) for children with baseline titers 
<1:10 versus 0.9 (95% CI: 0.8-1.1) those with  baseline titers ≥ 1:10 (A/H1N1), 3.8 (95% CI: 2.4-5.8) for 
baseline titers <1:10 versus 1.0 (95% CI: 0.90-1.04) for baseline titers ≥ 1:10 (A/H3N2), and 2.6 (95% 
CI: 2.2-3.1) for baseline titers <1:10 versus 0.8 (95% CI: 0.7-1.0) for baseline titers ≥ 1:10 (B antigens).8   
Seven studies calculated SCR (Supplemental Table 2).9,22,25,28,29,31,33 SCR were heterogenous 
across studies, ranging from 4% (95% CI: 0.10-19.6) to 70% (95% CI: 46-88) after one dose and 73% 
(95% CI: 52.2-88.4) to 98% (95% CI: 92.6-99.7) after two doses for A/H1N1; from 43% (95% CI: 33-53) 
to 89% (95% CI: 86-91) after one dose and 73.7% (95% CI: 62.3.2-85.1) to 100% (95% CI: 89.7-100) 
after two doses for A/H3N2; and from 2% (95% CI: 0.0-5.2) to 68% (95% CI: 57.8-77.1) after one dose 
and 19% (95% CI: 12-28) to 97% (95% CI: 91.0-99.3) after two doses for B antigens (Supplemental 
Table 2).  In general, a greater proportion of children seroconverted after two doses of IIV compared to 
one dose for all influenza strains. SCR were higher for older children and those with detectable baseline 
pre-vaccination titers (i.e. titers ≥1:10 or ≥1:8).9,22,29  While both of these groups had higher SCR after one 
dose compared to younger children and those with undetectable baseline antibody titers, all SCR 
increased after the second dose irrespective of age or baseline antibody titer status.   
Immunogenicity by vaccine schedule and strain composition 
 
 Two trials looked antibody response after alternative dosing schedules.23,32 Both studies 
administered one dose in the spring and the second in the fall (the early group) and compared antibody 
responses to a standard dosing group who received two doses in the fall spaced approximately 4 weeks 
apart. The studies differed by vaccine antigen composition where one administered an antigenically 
identical vaccine for both doses,23 and the other administered  2003-2004 and 2004-2005 vaccines which 
had different A/H3N2 and B vaccine antigen components to the early group.32 Antibody response after 
two doses was similar across groups in the study where antigenically identical vaccines were 
administered. GMTs for A/H1N1 (57.2 ± 4.2 vs 47.7 ± 3.1), A/H3N2 (129 ± 3.7 vs 114.6 ± 3.3  ), and B 
vaccine antigens (28.1 ± 3.9 vs 24.3 ± 3.9) for the early vs standard group.23 Similarly, the study where 
vaccine composition differed in the early group found that when antigen composition were identical as 
was the case for the A/H1N1 components of the vaccines, there was a comparable antibody response after 
two doses (early group GMTs= 79.5 ± 3.3 vs standard group GMTs= 91.9 ± 2.6).32  However, antibody 
response was less robust when antigen components differed across the two doses with a poorer antibody 
response as differences increased. For example GMTs after two doses were more comparable across 
groups for A/H3N2 which was antigenically similar but not identical (early group GMTs= 57.1 ± 4.1 vs 
standard group GMTs= 77.8  ± 3.7) than for B vaccine antigens which had major antigenic changes 
across doses (early group GMTs= 18.0 ± 2.4 vs standard group GMTs= 61.6 ± 2.5).32  
Another study compared antibody response in children who received two doses across the 2003-
2004 and 2004-2005 seasons (antigenically different vaccines) to children who received two doses in the 
2004-2005 season (antigenically identical vaccines).24 Again, results showed comparable antibody 
response between groups for the unchanged A/H1N1 antigen (GMTs 75.2 vs 69.1) 24  Surprisingly, 
A/H3N2 GMTs were significantly higher in the group that received the two doses across seasons 
(GMTS= 156; 95% CI 105-231) compared to the antigenically identical vaccine group (GMTS= 53.7; 
95% CI 41-70).24 However the former group was older and a higher percentage were alive during the 
previous influenza season where A/H3N2 was circulating. In contrast, antibody response to B vaccine 
antigens (antigen components differed greatly across seasons) was significantly lower after the second 
dose of IIV for the group that received doses across seasons (GMT= 13.8; 95% CI 11-17) compared to the 
group given identical vaccines in the same season (GMT=49.1; 95% CI 41-59).24 
Discussion  
To our knowledge this is the first to systematically review the current evidence on both the 
immunogenicity of two doses versus one dose of IIV and VE against influenza-related medical visits in 
PV and FV children from 6 months through 8 years.  Our objectives were to evaluate whether 
immunogenicity or VE varied by age with special attention to younger children (6-23 months) who are at 
higher risk of influenza related complications and older children who may not benefit from an additional 
dose of IIV due to natural priming, timing of doses (i.e. vaccine schedule), antigenic differences between 
both doses, and baseline pre-vaccination antibody titers. Our review included 10 VE studies, and 16 
immunogenicity studies to compare outcomes after one and two doses of IIV.  
Overall our findings suggest that a full two-dose influenza vaccine series in children receiving 
influenza vaccine for the first time provides more optimal protection against influenza-related medical 
visits in the first season of vaccination with a higher VE for FV children compared to PV children. 
Results were consistent across a variety of study designs.  While one of the VE studies did not find higher 
VE for FV children compared to PV children, this may be explained by a small sample size of PV 
children.20 Whether PV or a single dose influenza vaccine provides protection in a child’s first season of 
influenza vaccinations remains unclear. While some of the studies showed significant VE against 
influenza for PV children, these studies showed higher VE for FV children with the exception of 
Thompson et al., likely due to  small PV sample size.13,15,16,20   Interestingly two studies that estimated VE 
against influenza subtype found relatively higher VE against A/H3N2 for PV children compared to FV 
children.13,20  When considering the youngest age group, 6-23 months, VE was consistently low for PV 
children, highlighting the importance of full vaccination especially in young children. 
We also found increased immunogenicity after two doses of IIV compared to one dose for 
children 6 months through 8 years of age. GMR was typically > 1 across all three vaccine antigens 
indicating higher GMTs after the second dose with the exception of children with higher baseline 
antibody titers,8-10 and a history of influenza vaccination.27  GMR also tended to be higher among the 
youngest age group (children 6- 23 months) and children with non-detectable baseline titers indicating 
true immunologic naivety. Similarly, MFR or value increase of GMTs from baseline were higher post 
dose two compared to post dose one, with the exception of children with a history of influenza 
vaccination or positive baseline antibody titers were there was either no or minimal increase. These 
findings suggest that children who have exposure to influenza antigen either through previous vaccination 
or natural infection are may have an adequate immunologic response after a single dose (GMR ≤1 or 
MFR remained relatively unchanged or minimally increased after dose one and dose two).  
The two studies that compared an early vaccine schedule to a standard vaccine schedule found 
similar antibody responses irrespective of timing between doses when vaccine antigens were identical 
across doses,23,32 with worsening antibody response as antigen differences increased across doses.32  The 
importance of similar vaccine antigen composition across doses was again highlighted in another study 
that compared antibody response that received two doses across two seasons where the A/H1N1 vaccine 
antigens were identical, but the A/H3N2 and B vaccine antigen differed. Again, results found comparable 
antibody response for A/H1N1 (identical antigens) but not A/H3N2 or B vaccine antigens across groups.24 
Our findings suggest that timing between doses or vaccination schedule does not affect immunogenicity 
when vaccine antigen components are identical. In contrast, vaccine antigen composition does appear to 
influence antibody response. These findings suggest that administering the first of the two recommended 
doses early may be appropriate especially across seasons where vaccines antigen components are 
unchanged, which may help with the logistical challenges of getting two doses before the start of the 
influenza season.  
Thompson et al. found higher VE for the current season among children who were primed with 
two doses of influenza vaccine in the same prior season compared to alternative definitions of priming.20 
These findings highlight the importance of two doses of influenza vaccine not only to provide protection 
against influenza for the current season, but to adequately prime the immune system for future influenza 
seasons. Indeed, the study also found residual protection in children previously vaccinated but whom 
missed the current season IIV (VE=36%-40%), even in seasons where antigen components had changed 
across years.20  Interestingly these findings seem to contradict the immunogenicity studies which 
highlight the importance of antigen similarly between doses. This may be explained by the fact that 
immunogenicity trials typically evaluate HAI antibodies and may be missing another component that is 
critical to immune response and protection. 
SCR was consistently higher after two doses of IIV compared to one dose for all vaccine 
antigens. While older children had higher SCR compared to younger children after one dose, SCR 
increased from post dose one to post dose two of IIV across all age groups.  The current definition of 
SCR, which uses a post-vaccination HAI titer > 1:40 for those with undetectable baseline antibody titers, 
is based largely from adult studies where a 1:40 HAI titer is generally thought to correspond to a 50% 
decrease in risk of influenza infection and is cited as a relative, but not absolute, correlate of 
protection.35,36 In contrast, a  paper by Black et al. showed that a 1:40 HAI is associated with only a 22% 
protection rate in children less than 6 years of age, and identified a cutoff HAI titer of 1:110 as a better 
correlate of protection for young children.37 Indeed, the three studies that changed the threshold to higher 
HAI titers found that a lower percentage of children were considered seroprotected after two doses of 
IIV.26,28,31  
This review had some limitations. Few studies included the oldest group within the 6 months 
through 8 years age range and most of the studies focused on children ≤ 5 years.  We did not identify any 
VE studies with children > 5 years. We were therefore had limited data to make conclusions about the 
oldest group within the ACIP age range. Another limitation was that the majority of immunogenicity 
trials administered a 0.25 ml dose for children < 3 years, and 0.5 ml dose for children ≥3 years. Now there 
are multiple doses licensed for use in children and therefore it is unclear whether our findings apply to 
higher doses. Still another limitation to our review was the immunogenicity trials only focused of HAI 
antibody titers as a correlate of protection. However, correlates of protection are not fully understood 
especially in children as there are other immune functions that likely play a role in protection, such as 
cell-mediated immunity and anti-neuraminidase antibodies, which are not captured by HAI assays.  
In conclusion, the current evidence suggests that two doses of IIV provides more protection 
against influenza related medical illness compared to one dose in children ages 6 months through 8 years, 
supporting the current ACIP recommendations. This is based on immunogenicity studies that found 
higher GMTs and SCR after two doses compared to one dose of IIV and studies that found relatively 
higher VE against influenza for FV compared to PV children.  This is especially true for younger children 
and those without baseline antibody titers, indicating they are truly vaccine naïve. Children with positive 
baseline antibody titers may have adequate protection after only one dose of IIV however this is not 
clinically applicable as baseline antibody titers are typically not measured in the clinical setting. Future 
studies should focus on children < 5 years of age, consider higher HAI titers as a correlate of protection, 
and focus on identifying other potential markers of protection for children. 
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Figure 1. Flow diagram of Included Studies: Preferred reporting items for systematic reviews and meta-
analysis 
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 Study Design 
Sample 
size Country Age groups Season(s)   
 Vaccine Effectiveness          
 
 
 Allison 2006 cohort n= 5193 United 
States 
6-21 month 2003 - 
2004 
 
 
 
Buchan 2017 case-
control 
n=9982 Canada 6-59 months 2010-2011 
to 2013-
2014 
 
 
 Eisenberg 2008 case-
control 
n= 2474 United 
States 
6-59 months 2003-2004 
2004-2005 
 
 
 
Joshi 2009 case-
control 
n= 206 United 
States 
6-59 months 1999-2002 
to 2006-
2007 
 
 
 Ritzwoller 2005 cohort n= 29726 United 
States 
6 months 
through 8 years 
2003 - 
2004 
 
 
 
Segaloff 2019 case-
control 
n=3147 Israel 6 months 
through 8 years 
2015-2016 
to 2017-
2018 
 
 
 Shuler 2007 case-
control 
n= 870 United 
States 
6-59 months 2003-2004 
 
 
 Staat 2011 case-
control 
n=528 United 
States 
6-59 months 2005-2006 
2006-2007 
 
 
 Szilagyi 2008 case-
control 
n=10,492 United 
States 
6-59 months 2003-2004 
2004-2005 
 
 
 Thompson 2016  case-
control 
n= 2768 United 
States 
6 months 
through 8 years 
2011-2012 
2012-2013 
 
 
 
Immunogenicit
y             
 
Bernstein 1982ß cohort n= 77 United 
States 
6-36 months 1978-1979   
1979-1980   
 
Diallo 2018ꝿꞱ RCT n= 93 Senegal 6-71 months 2012-2013   
 Englund 2005 RCT n=259 United 
States 
6-23 months 2003-2004  
 Englund 2006 cohort n=119 United 
States 
6-23 months 2004-2005 
 
 
 Hwang 2014 cohort n= 59 Taiwan 6-12 months 2010-2011 
 
 
 Ito 2018 cohort n=266 Japan 6-47 months 2006-2007 
 
 
 Mugitani 2014∫ cohort n= 259 Japan 6-47 months 2005-2006 
 
 
 Neuzil 2006 cohort n=222 United 
States 
5 through 8 
years  
2004-2005 
 
 
 Nolan 2009 cohort n=298 Australia 6 months 
through 8 years 
2005, 
2006 
 
 
 Nolan 2014ꝿꞱ RCT n= 820 MultipleՀ 6-71 months 2011-2012 
 
 
 
         
  
Table 1. Studies comparing immunogencity of one versus two doses of inactivated influenza vaccine or 
evaluating vaccine effectiveness in partially vaccinated and fully vaccinated healthy children 6 months 
through 9 years of age, N=26 
 Schmidt-Ott 
2007 
cohort n=110 Germany 
6 through 9 
years 
2005-2006 
 
 
 Solares 2014 RCT n= 122 Guatemala 6-59 months 2008 
 
 
 Vesikari 2011ꝿ RCT n=319 Finland 6-71 months  2008-2009 
 
 
 Vesikari 2018ꝿ RCT n=866 Multipleꭞ 6-59 months 2013-2014  
2014-2015 
 
 
 Walter 2006 RCT n=468 United 
States 
6-23 months 2004-2005 
 
 
 Wright 2008 cohort n= 43 United 
States 
6-23 months 2002-2003 
 
 
 
         
  
 
      
 
 
 
      
 
 
 
      
 
 
 
      
 
 
 
      
 
 
 
      
 
 
 
      
 
 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
RCT: randomized controlled trial;  
Vaccine dosage 0.25 ml/ dose for children <3 years and  0.5ml/dose for children ≥3 years unless otherwise 
specified. The majority of the studies assess VE and immunogenicity for trivalent inactivated vaccine. 
ß Bernstein 1982 & Wright 1983: First dose monovalent A/USSR/77 (H1N1), second dose trivalent A/USSR/77 
(H1N1), A/Texas/77 (H3N2), and B/Hong Kong/72. 
ꝿ Diallo 2018, Nolan 2014, Vesikari 2011, and Vesikari 2018: Studies compared adjuvanted versus 
unadjuvanted. influenza vaccines in children. Reported data is from groups that received unadjuvanted 
vaccines only. 
Ʇ Diallo 2018 and Nolan 2014: All children received 0.5 ml/dose regardless of age. 
∫ Mugitani 2014: Low dose trial; 0.1ml/ dose for children <1 years and 0.2ml/dose for children ≥1 years.   
Հ Five countries including Argentina, Australia, Chile, Philippines, and South Africa. 
ꭞ Nine countries including Finland, USA, Canada, Italy, Poland, Spain, Philippines, Thailand, and Taiwan. 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 HAI: hemagglutination inhibition; GMTs: geometric mean titers; GMR: geometric mean titers ratio;  CI: Confidence interval; m: months; y: years;  
Blood serum collected approximately four weeks post vaccination unless otherwise noted. Mean fold rise was estimated as log2 post vaccination 
GMTs after one dose or post vaccincation GMTs after two doses divided by log2 baseline GMTs.  GMR was estimated as log2 post vaccination GMTs 
after two doses  divided by log2 post vaccination GMTs after one dose.  
¥ Vaccine naïve is defined as children who have never received influenza vaccine prior to the study. 
ß Bernstein 1983: First dose H1N1 monovalent vaccine, second dose trivalent vaccine. Second dose was first exposure to A/H3N2 and B antigens in 
the study period  
ꝿ Diallo 2018, Nolan 2014, Solares 2014, Vesikari 2011, and Vesikari 2018: Studies compared adjuvanted versus unadjuvanted influenza vaccines in 
children. Reported data is from groups that received unadjuvanted vaccines only. 
Ʇ Diallo 2018 and Nolan 2014: All children received 0.5 ml/dose regardless of age. 
« Nolan 2014:  94-99% of subjects were vaccine naïve. 
α Assigned value, no variation 
* Data for total group include vaccine naïve and vaccine experienced subjects. 
¶ Data where n=4 not shown in Wright 2008 study. 
∫ Mugitani 2014 0.1ml/ dose for children <1 years and 0.2ml/dose for children ≥1 years.  
Ɽ A figure converter was used to collect data for Englund 2005, Englund 2006, Walter 2006, and Nolan 2014. 
ꭜ Nolan 2014, Schmidt-Ott 2007, Solares 2014, Vesikari 2011, and Vesikari 2018: Serum samples collected four weeks after first vaccination and 
three weeks after second vaccination. 
          
  
 
  
  
      Buchan 2017   
Segaloff 
2019   Thompson 2016Þ 
      VE% (95% CI)   VE% (95% CI)   
VE% (95% 
CI)   
     PV FV PV FV PV FV 
  
Influenza A 
(all) 
50.5 (26.0-
66.9) 
60.7 (38.9-
74.7) 
45.1 (12.3-
67.1) 
63.9 (38.7-
80.1)     
                
  A/H1N1  
31.5 (-41.4 to 
66.8) 
82.1 (27.3-
98.6)        
                
  A/ H3N2  
69.6 (25.2-
87.7) 
53.3 (3.5-
77.4)    83 (60-93) 
36 (6-
56) 
                
  
Influenza 
B   
11.8 (-44.8 to 
46.2) 
58.0 (28.3-
75.4) 
4.1 (-45.4 to 
38.1) 
42.3 (8.6-
64.9) 52 (10-74) 
59 (40-
72) 
 
 
 
 
 
 
 
 
 
 
  
Supplemental Table 1: Vaccine Effectiveness estimates by Influenza subtype from case-control trials with 
laboratory confirmed influenza endpoint, N=3 
PV: partially vaccinated; FV: fully vaccinated; VE: vaccine effectiveness; CI: confidence interval 
 
